Drug Safety Research Unit

Pharmacy Market

Businesswire | August 18, 2023

Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its Neuroscience Toolkit into research programs. The first collaboration of the KAPP-PD program, with Oregon Health & Science University (OHSU), enables the inclusion of app-and actigraphy-based digital measures and electronic patient reported outcome (...

Send Press Releases with GlobeNewswire | March 06, 2020

Tetra Bio-Pharma Inc a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an investor relations, management consulting and financial communications firm to implement and execute a comprehensive investor relations and communications program. “I am very pleased and excited to have engaged Alpha Bronze as our new IR firm. They have demonstrated in a recent mandate provided to them that...

Pharma Tech

n-Lorem a nonprofit Foundation | January 20, 2022

n-Lorem, a nonprofit Foundation, discovering and providing experimental antisense oligonucleotide medicines to nano-rare disease patients for free, for life, today announced a new partnership with Alnylam Pharmaceuticals Inc. “Discovering, developing and providing individualized medicines for nano-rare patients is a monumental task. At n-Lorem, using ASO technology, we take advantage of three decades of experience, unparalleled quality control and integrated safety databases...

Moleculin Biotech, Inc | October 07, 2020

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...